The Hill: Pharma flap imperils president’s trade deal
“…The exact details of the pharmaceutical provision [contained in the Trans-Pacific Partnership], which involves a class of drugs called biologics, won’t be made public until later this month. Still, it’s already threatening to drag out — and possibly derail — the approval process for a deal reached by a dozen nations that together make up 40 percent of the world’s gross domestic product…” (Ferris, 10/20).